Aytu Biopharma, INC Form 4 insider transactions

Joshua R. Disbrow, Chief Executive Officer and a Director of Aytu Biopharma, Inc, received 30,000 shares of common stock on July 28, 2026.

Greg Pyszczymuka, Chief Commercial Officer of Aytu Biopharma, Inc, received 20,000 shares of common stock on July 28, 2026.

Jarrett Disbrow, Chief Business Officer of Aytu Biopharma, Inc, received 15,000 shares of common stock on July 28, 2026.

Ryan J Selhorn, Chief Financial Officer of Aytu Biopharma, Inc, received 25,000 shares of common stock on July 28, 2026.

Vivian H Liu, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Abhinav Jain, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

Carl Dockery, a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

John Donofrio Jr., a Director of Aytu Biopharma, Inc, received 10,000 shares of common stock on July 28, 2026.

AYTU BioPharma's Chief Commercial Officer, Greg Pyszczymuka, was granted 12,500 shares of restricted common stock.

AYTU BioPharma's Chief Business Officer, Jarrett Disbrow, was granted 32,106 shares of common stock as part of his compensation, including an annual bonus and restricted stock with a vesting schedule.

AYTU BioPharma's Chief Financial Officer, Ryan J. Selhorn, increased his beneficial ownership by 33,743 shares through restricted stock grants.

AYTU BioPharma's CEO, Joshua R. Disbrow, increased his direct beneficial ownership by 53,946 shares through restricted stock grants on October 3, 2025.

AYTU BioPharma Director Vivian H. Liu was granted 10,000 shares of restricted common stock, vesting on October 3, 2026.

AYTU BioPharma Director Abhinav Jain was granted 10,000 shares of common stock, vesting in October 2026, increasing his beneficial ownership to 19,500 shares.

AYTU BioPharma, Inc. Director Carl Dockery was granted 10,000 shares of restricted common stock, vesting on October 3, 2026.

AYTU BioPharma Director John Donofrio Jr. was granted 10,000 shares of common stock, vesting in October 2026, increasing his direct beneficial ownership to 13,762 shares.

AYTU BioPharma's Chief Business Officer, Jarrett Disbrow, has acquired 16,666 shares of common stock at $1.50 per share, signaling management confidence in the company's future.

AYTU BioPharma's CEO, Joshua R. Disbrow, acquired 66,666 shares of common stock at $1.50 per share, increasing his direct beneficial ownership to 153,257 shares.

Nantahala Capital Management, along with directors Wilmot B. Harkey and Daniel Mack, reported the acquisition of 4 million prefunded warrants in Aytu BioPharma, Inc., signaling increased beneficial ownership.

Chief Commercial Officer Greg Pyszczymuka reports the vesting of restricted stock units into Aytu BioPharma common shares.

Ryan Selhorn, CFO of Aytu BioPharma, reports the vesting and disposal of restricted stock units.

Aytu BioPharma's CEO, Joshua R. Disbrow, recently purchased 15,000 shares of the company's common stock in open market transactions.

Chief Commercial Officer Greg Pyszczymuka reports the vesting of restricted stock units in Aytu BioPharma.

Aytu BioPharma's Chief Financial Officer, Ryan Selhorn, acquired 14,000 shares of restricted stock on November 11, 2024.

Director Carl Dockery acquired 1,500 common shares of Aytu BioPharma, Inc. on November 6, 2024.

Director John Donofrio Jr. of Aytu BioPharma, Inc. was granted 1,500 common shares of restricted stock on November 6, 2024, vesting on the earlier of November 6, 2025, or the next annual stockholder meeting.

Director Abhinav Jain reports acquiring 1,500 common shares of Aytu BioPharma, Inc. through a grant of restricted shares.

CEO Joshua Disbrow reports acquisition of 38,000 employee stock options in Aytu BioPharma, Inc.

Jarrett Disbrow, Chief Business Officer of Aytu BioPharma, acquired 7,000 employee stock options on November 6, 2024.

Vivian H. Liu, a director of Aytu BioPharma, acquired 1,500 common shares through a restricted stock grant that vests on November 6, 2025, or at the next annual stockholder meeting.